Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qnk9Xb3
via IFTTT